Wednesday, September 11th, 2019.  Mr Charles Garvey, Metabolomic Diagnostics’ CEO is attending RESI (Redefining Early Stage Investments) in Boston today.

RESI is a global gathering of fundraising executives, entrepreneurs, service providers to healthcare investors and strategic partners. RESI connects companies with global investors across the “4 Ds” of drugs, devices, diagnostics and digital health.

Metabolomic Diagnostics is a biomarker-based diagnostics company based in Cork, Ireland and is focused on developing a portfolio of early pregnancy screening test.

The company’s first product, PrePsia™, is focused on Pre-term Preeclampsia screening for First time pregnancies which is an unmet clinical need. This is a serious disease that can cause major disruption during pregnancy leading to the deaths of Mums and Babies and can have serious life-long consequences for the survivors.